Skip Navigation

Journal of Antimicrobial Chemotherapy 2005 55(Supplement 2):ii21-ii24; doi:10.1093/jac/dki007
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lopez, S.
Right arrow Articles by Goldstein, B. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lopez, S.
Right arrow Articles by Goldstein, B. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved

Supplement

In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide

Sara Lopez1, Corinne Hackbarth1, Gabriella Romanò2, Joaquim Trias1, Daniela Jabes2 and Beth P. Goldstein3,*

1 Vicuron Pharmaceuticals, Fremont, CA; 3 Vicuron Pharmaceuticals, King of Prussia, PA, USA; 2 Vicuron Pharmaceuticals, Via R. Lepetit 34-21040 Gerenzano, Varese, Italy

* Corresponding author. Tel: +1-610-491-2209; Fax: +1-610-491-2229; Email: bgoldstein{at}vicuron.com

Objectives: Dalbavancin is a novel, semi-synthetic glycopeptide antibiotic. The aim of this study was to further explore its activity against staphylococci.

Methods: The bactericidal activity of dalbavancin was studied using MBC and time–kill methods. The potential for resistance to dalbavancin was examined using single-step and serial-passage experiments.

Results: Dalbavancin was bactericidal against methicillin-susceptible and -resistant Staphylococcus aureus, in both the presence and absence of human serum. No resistance was seen with any isolate tested. After serial passage, bacterial populations were more homogeneous in their susceptibility to dalbavancin than to vancomycin or teicoplanin.

Conclusion: Dalbavancin is bactericidal for staphylococci. Resistance to this semi-synthetic glycopeptide is not readily developed in vitro.

Keywords: bactericidal activity , resistance , staphylococci


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
R. J. Attwood and K. L. LaPlante
Telavancin: A novel lipoglycopeptide antimicrobial agent
Am. J. Health Syst. Pharm., November 15, 2007; 64(22): 2335 - 2348.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
B. P. Goldstein, D. C. Draghi, D. J. Sheehan, P. Hogan, and D. F. Sahm
Bactericidal Activity and Resistance Development Profiling of Dalbavancin
Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1150 - 1154.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
D. J. Biedenbach, J. E. Ross, T. R. Fritsche, H. S. Sader, and R. N. Jones
Activity of Dalbavancin Tested against Staphylococcus spp. and {beta}-Hemolytic Streptococcus spp. Isolated from 52 Geographically Diverse Medical Centers in the United States
J. Clin. Microbiol., March 1, 2007; 45(3): 998 - 1004.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S.-W. Lin, P. L Carver, and D. D DePestel
Dalbavancin: A New Option for the Treatment of Gram-Positive Infections
Ann. Pharmacother., March 1, 2006; 40(3): 449 - 460.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.